FDA
-
-
-
-
-
-
-
PDS Biotech schedules FDA meeting on accelerated approval pathway
-
-
-
-
-
-
-
PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC
-
-
-
-
-
-
-
PDS Biotechnology (PDSB) Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer
-
-
-
-
-
-
-
PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET
-
-
-
-
-
-
-
PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024
-
-
-
-
-
-
-
Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer
-
-
-
-
-
-
-
PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

